Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Assessment of disease progression in dysferlinopathy: A 1-year cohort study.

Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V; Jain COS Consortium.

Neurology. 2019 Jan 9. pii: 10.1212/WNL.0000000000006858. doi: 10.1212/WNL.0000000000006858. [Epub ahead of print]

2.

Conducting an investigator-initiated randomized double-blinded intervention trial in acute decompensation of inborn errors of metabolism: Lessons from the N-Carbamylglutamate Consortium.

Ah Mew N, Cnaan A, McCarter R, Choi H, Glass P, Rice K, Scavo L, Gillespie CW, Diaz GA, Berry GT, Wong D, Konczal L, McCandless SE, Coughlin Ii CR, Weisfeld-Adams JD, Ficicioglu C, Yudkoff M, Enns GM, Lichter-Konecki U, Gallagher R, Tuchman M.

Transl Sci Rare Dis. 2018 Dec 20;3(3-4):157-170. doi: 10.3233/TRD-180031.

3.

Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids.

McDonald CM, Gordish-Dressman H, Henricson EK, Duong T, Joyce NC, Jhawar S, Leinonen M, Hsu F, Connolly AM, Cnaan A, Abresch RT; CINRG investigators for PubMed.

Neuromuscul Disord. 2018 Nov;28(11):897-909. doi: 10.1016/j.nmd.2018.07.004. Epub 2018 Aug 29.

4.

Maternal and child patterns of Medicaid retention: a prospective cohort study.

Pati S, Calixte R, Wong A, Huang J, Baba Z, Luan X, Cnaan A.

BMC Pediatr. 2018 Aug 21;18(1):275. doi: 10.1186/s12887-018-1242-4.

5.

A multinational study on motor function in early-onset FSHD.

Mah JK, Feng J, Jacobs MB, Duong T, Carroll K, de Valle K, Carty CL, Morgenroth LP, Guglieri M, Ryan MM, Clemens PR, Thangarajh M, Webster R, Smith E, Connolly AM, McDonald CM, Karachunski P, Tulinius M, Harper A, Cnaan A, Chen YW; Cooperative International Neuromuscular Research Group (CINRG) Investigators.

Neurology. 2018 Apr 10;90(15):e1333-e1338. doi: 10.1212/WNL.0000000000005297. Epub 2018 Mar 14.

6.

Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study.

Moore UR, Jacobs M, Fernandez-Torron R, Jang J, James MK, Mayhew A, Rufibach L, Mittal P, Eagle M, Cnaan A, Carlier PG, Blamire A, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Diaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1224-1226. doi: 10.1136/jnnp-2017-317329. Epub 2018 Jan 29. No abstract available.

7.

Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.

McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H; CINRG Investigators.

Lancet. 2018 Feb 3;391(10119):451-461. doi: 10.1016/S0140-6736(17)32160-8. Epub 2017 Nov 22.

PMID:
29174484
8.

Pretreatment behavior and subsequent medication effects in childhood absence epilepsy.

Shinnar RC, Shinnar S, Cnaan A, Clark P, Dlugos D, Hirtz DG, Hu F, Liu C, Masur D, Weiss EF, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2017 Oct 17;89(16):1698-1706. doi: 10.1212/WNL.0000000000004514. Epub 2017 Sep 15.

9.

Pretreatment seizure semiology in childhood absence epilepsy.

Kessler SK, Shinnar S, Cnaan A, Dlugos D, Conry J, Hirtz DG, Hu F, Liu C, Mizrahi EM, Moshé SL, Clark P, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2017 Aug 15;89(7):673-679. doi: 10.1212/WNL.0000000000004226. Epub 2017 Jul 19.

10.

Do changes in socio-demographic characteristics impact up-to-date immunization status between 3 and 24 months of age? A prospective study among an inner-city birth cohort in the United States.

Pati S, Huang J, Wong A, Baba Z, Ostapenko S, Fiks AG, Cnaan A.

Hum Vaccin Immunother. 2017 May 4;13(5):1141-1148. doi: 10.1080/21645515.2016.1261771. Epub 2017 Feb 27.

11.

Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy.

Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, Cnaan A, Dlugos D, Hirtz DG, Shinnar S, Grabowski G; Childhood Absence Epilepsy Study Group.

Ann Neurol. 2017 Mar;81(3):444-453. doi: 10.1002/ana.24886.

12.

Second monotherapy in childhood absence epilepsy.

Cnaan A, Shinnar S, Arya R, Adamson PC, Clark PO, Dlugos D, Hirtz DG, Masur D, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2017 Jan 10;88(2):182-190. doi: 10.1212/WNL.0000000000003480. Epub 2016 Dec 16.

13.

The Clinical Outcome Study for dysferlinopathy: An international multicenter study.

Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, Smith FE, Rufibach L, Cnaan A, Bharucha-Goebel DX, Blamire AM, Bravver E, Carlier PG, Day JW, Díaz-Manera J, Eagle M, Grieben U, Harms M, Jones KJ, Lochmüller H, Mendell JR, Mori-Yoshimura M, Paradas C, Pegoraro E, Pestronk A, Salort-Campana E, Schreiber-Katz O, Semplicini C, Spuler S, Stojkovic T, Straub V, Takeda S, Rocha CT, Walter MC, Bushby K; Jain COS Consortium.

Neurol Genet. 2016 Aug 4;2(4):e89. doi: 10.1212/NXG.0000000000000089. eCollection 2016 Aug.

14.

Obesity and overweight as CAE comorbidities and differential drug response modifiers.

Arya R, Gillespie CW, Cnaan A, Devarajan M, Clark P, Shinnar S, Vinks AA, Mizuno K, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2016 Apr 26;86(17):1613-21. doi: 10.1212/WNL.0000000000002611. Epub 2016 Mar 30.

15.

Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial.

Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Moshé SL, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2015 Sep 29;85(13):1108-14. doi: 10.1212/WNL.0000000000001971. Epub 2015 Aug 26.

16.

Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, Cnaan A, McDonald CM; CINRG Investigators.

Neurology. 2015 Sep 22;85(12):1048-55. doi: 10.1212/WNL.0000000000001950. Epub 2015 Aug 26.

17.

Longitudinal Change of Circumpapillary Retinal Nerve Fiber Layer Thickness in Children With Optic Pathway Gliomas.

Avery RA, Cnaan A, Schuman JS, Trimboli-Heidler C, Chen CL, Packer RJ, Ishikawa H.

Am J Ophthalmol. 2015 Nov;160(5):944-952.e1. doi: 10.1016/j.ajo.2015.07.036. Epub 2015 Jul 29.

18.

Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies.

Spurney CF, McCaffrey FM, Cnaan A, Morgenroth LP, Ghelani SJ, Gordish-Dressman H, Arrieta A, Connolly AM, Lotze TE, McDonald CM, Leshner RT, Clemens PR.

J Am Soc Echocardiogr. 2015 Aug;28(8):999-1008. doi: 10.1016/j.echo.2015.03.003. Epub 2015 Apr 21.

19.

Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome.

Kessler SK, McCarthy A, Cnaan A, Dlugos DJ.

Epilepsy Res. 2015 May;112:18-26. doi: 10.1016/j.eplepsyres.2015.02.003. Epub 2015 Feb 14.

20.

Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.

Bello L, Kesari A, Gordish-Dressman H, Cnaan A, Morgenroth LP, Punetha J, Duong T, Henricson EK, Pegoraro E, McDonald CM, Hoffman EP; Cooperative International Neuromuscular Research Group Investigators.

Ann Neurol. 2015 Apr;77(4):684-96. doi: 10.1002/ana.24370. Epub 2015 Mar 13.

21.

Clinical and genetic characterization of a founder PKHD1 mutation in Afrikaners with ARPKD.

Lambie L, Amin R, Essop F, Cnaan A, Krause A, Guay-Woodford LM.

Pediatr Nephrol. 2015 Feb;30(2):273-9. doi: 10.1007/s00467-014-2917-1. Epub 2014 Sep 6.

PMID:
25193386
22.

Intra- and inter-visit reproducibility of ganglion cell-inner plexiform layer measurements using handheld optical coherence tomography in children with optic pathway gliomas.

Avery RA, Cnaan A, Schuman JS, Chen CL, Glaug NC, Packer RJ, Quinn GE, Ishikawa H.

Am J Ophthalmol. 2014 Nov;158(5):916-23. doi: 10.1016/j.ajo.2014.07.029. Epub 2014 Jul 25.

23.

Reproducibility of circumpapillary retinal nerve fiber layer measurements using handheld optical coherence tomography in sedated children.

Avery RA, Cnaan A, Schuman JS, Chen CL, Glaug NC, Packer RJ, Quinn GE, Ishikawa H.

Am J Ophthalmol. 2014 Oct;158(4):780-787.e1. doi: 10.1016/j.ajo.2014.06.017. Epub 2014 Jun 28.

24.

Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas.

Gu S, Glaug N, Cnaan A, Packer RJ, Avery RA.

Invest Ophthalmol Vis Sci. 2014 Mar 10;55(3):1402-8. doi: 10.1167/iovs.13-13119.

25.

Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy.

Masur D, Shinnar S, Cnaan A, Shinnar RC, Clark P, Wang J, Weiss EF, Hirtz DG, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2013 Oct 29;81(18):1572-80. doi: 10.1212/WNL.0b013e3182a9f3ca. Epub 2013 Oct 2.

26.

The influence of maternal health literacy and child's age on participation in social welfare programs.

Pati S, Siewert E, Wong AT, Bhatt SK, Calixte RE, Cnaan A.

Matern Child Health J. 2014 Jul;18(5):1176-89. doi: 10.1007/s10995-013-1348-0.

27.

The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.

Sali A, Many GM, Gordish-Dressman H, van der Meulen JH, Phadke A, Spurney CF, Cnaan A, Hoffman EP, Nagaraju K.

PLoS One. 2013 Jul 2;8(7):e66617. doi: 10.1371/journal.pone.0066617. Print 2013.

28.

Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome.

Dlugos D, Shinnar S, Cnaan A, Hu F, Moshé S, Mizrahi E, Masur D, Sogawa Y, Le Pichon JB, Levine C, Hirtz D, Clark P, Adamson PC, Glauser T; Childhood Absence Epilepsy Study Team.

Neurology. 2013 Jul 9;81(2):150-6. doi: 10.1212/WNL.0b013e31829a3373. Epub 2013 May 29.

29.

The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR, Hoffman EP, Cnaan A; Cinrg Investigators.

Muscle Nerve. 2013 Jul;48(1):32-54. doi: 10.1002/mus.23807. Epub 2013 May 16.

30.

The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.

Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, Han J, Escolar DM, Florence JM, Clemens PR, Hoffman EP, McDonald CM; CINRG Investigators.

Muscle Nerve. 2013 Jul;48(1):55-67. doi: 10.1002/mus.23808. Epub 2013 May 6.

31.

Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T; ILAE Subcommission on AED Guidelines.

Epilepsia. 2013 Mar;54(3):551-63. doi: 10.1111/epi.12074. Epub 2013 Jan 25. Review.

32.

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team.

Epilepsia. 2013 Jan;54(1):141-55. doi: 10.1111/epi.12028. Epub 2012 Nov 21.

33.

Reading level of Medicaid renewal applications.

Pati S, Kavanagh JE, Bhatt SK, Wong AT, Noonan K, Cnaan A.

Acad Pediatr. 2012 Jul-Aug;12(4):297-301. doi: 10.1016/j.acap.2012.04.008. Epub 2012 Jun 7.

PMID:
22682719
34.

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, Kornberg AJ, Bertorini TE, Nevo Y, Lotze T, Pestronk A, Ryan MM, Monasterio E, Day JW, Zimmerman A, Arrieta A, Henricson E, Mayhew J, Florence J, Hu F, Connolly AM.

Neurology. 2011 Aug 2;77(5):444-52. doi: 10.1212/WNL.0b013e318227b164. Epub 2011 Jul 13.

35.

Medical radiation exposure and risk of retinoblastoma resulting from new germline RB1 mutation.

Bunin GR, Felice MA, Davidson W, Friedman DL, Shields CL, Maidment A, O'Shea M, Nichols KE, Leahey A, Dunkel IJ, Jubran R, Rodriguez-Galindo C, Schmidt ML, Weinstein JL, Goldman S, Abramson DH, Wilson MW, Gallie BL, Chan HS, Shapiro M, Cnaan A, Ganguly A, Meadows AT.

Int J Cancer. 2011 May 15;128(10):2393-404. doi: 10.1002/ijc.25565.

36.

Influence of maternal health literacy on child participation in social welfare programs: the Philadelphia experience.

Pati S, Mohamad Z, Cnaan A, Kavanagh J, Shea JA.

Am J Public Health. 2010 Sep;100(9):1662-5. doi: 10.2105/AJPH.2009.172742. Epub 2010 Jul 15.

37.

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group.

N Engl J Med. 2010 Mar 4;362(9):790-9. doi: 10.1056/NEJMoa0902014.

38.

Maternal health literacy and late initiation of immunizations among an inner-city birth cohort.

Pati S, Feemster KA, Mohamad Z, Fiks A, Grundmeier R, Cnaan A.

Matern Child Health J. 2011 Apr;15(3):386-94. doi: 10.1007/s10995-010-0580-0.

PMID:
20180003
39.

Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide.

Walsh MC, Hibbs AM, Martin CR, Cnaan A, Keller RL, Vittinghoff E, Martin RJ, Truog WE, Ballard PL, Zadell A, Wadlinger SR, Coburn CE, Ballard RA; NO CLD Study Group.

J Pediatr. 2010 Apr;156(4):556-61.e1. doi: 10.1016/j.jpeds.2009.10.011. Epub 2010 Feb 6.

40.

Accounting for multiple births in neonatal and perinatal trials: systematic review and case study.

Hibbs AM, Black D, Palermo L, Cnaan A, Luan X, Truog WE, Walsh MC, Ballard RA.

J Pediatr. 2010 Feb;156(2):202-8. doi: 10.1016/j.jpeds.2009.08.049. Epub 2009 Dec 6. Review.

41.

Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation.

Zupancic JA, Hibbs AM, Palermo L, Truog WE, Cnaan A, Black DM, Ballard PL, Wadlinger SR, Ballard RA; NO CLD Trial Group.

Pediatrics. 2009 Nov;124(5):1325-32. doi: 10.1542/peds.2008-3214. Epub 2009 Oct 19.

PMID:
19841125
42.

Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites.

Posencheg MA, Gow AJ, Truog WE, Ballard RA, Cnaan A, Golombek SG, Ballard PL; NO CLD Investigators.

J Perinatol. 2010 Apr;30(4):275-80. doi: 10.1038/jp.2009.155. Epub 2009 Oct 8.

43.

Visual assessment of jaundice in term and late preterm infants.

Keren R, Tremont K, Luan X, Cnaan A.

Arch Dis Child Fetal Neonatal Ed. 2009 Sep;94(5):F317-22. doi: 10.1136/adc.2008.150714. Epub 2009 Mar 22.

PMID:
19307221
44.

One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial.

Hibbs AM, Walsh MC, Martin RJ, Truog WE, Lorch SA, Alessandrini E, Cnaan A, Palermo L, Wadlinger SR, Coburn CE, Ballard PL, Ballard RA.

J Pediatr. 2008 Oct;153(4):525-9. doi: 10.1016/j.jpeds.2008.04.033. Epub 2008 Jun 4.

45.

Inhaled nitric oxide for preterm infants.

Truog WE, Martin RJ, Ballard RA, Black D, Cnaan A; NO CLD Study Group.

Pediatrics. 2008 Jun;121(6):1287-8; author reply 1288-9. doi: 10.1542/peds.2007-3450. No abstract available.

PMID:
18519502
46.

Elevated substance P levels in HIV-infected women in comparison to HIV-negative women.

Douglas SD, Cnaan A, Lynch KG, Benton T, Zhao H, Gettes DR, Evans DL.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):375-8. doi: 10.1089/aid.2007.0207.

PMID:
18327973
47.

Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants.

Ballard PL, Truog WE, Merrill JD, Gow A, Posencheg M, Golombek SG, Parton LA, Luan X, Cnaan A, Ballard RA.

Pediatrics. 2008 Mar;121(3):555-61. doi: 10.1542/peds.2007-2479.

PMID:
18310205
48.

A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants.

Keren R, Luan X, Friedman S, Saddlemire S, Cnaan A, Bhutani VK.

Pediatrics. 2008 Jan;121(1):e170-9. doi: 10.1542/peds.2006-3499.

PMID:
18166536
49.

Ethical and regulatory issues related to pregnancy registries and their outcomes.

French JA, Meador K, Cnaan A, Gilliam F, Conway J, Araojo R, Feibus K.

Epilepsy Behav. 2008 May;12(4):587-91. Epub 2007 Dec 26. Review.

PMID:
18158272
50.

The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.

Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, Cnaan A, Zhuang H, Phillips PC, Alavi A.

J Neurooncol. 2008 Apr;87(2):165-71. Epub 2007 Dec 11.

PMID:
18071635

Supplemental Content

Support Center